Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis

Inclusion Criteria: All patients who according to the compound's Norwegian prescription guidelines are deemed eligible for the study, i.e. MS patients with impaired walking as determined by an EDSS 4-7. They do not need a past history of optic neuritis, cognitive failure, fatigue or difficulties micturating. Exclusion Criteria: MS patients with contraindications to the compound according to the prescription guidelines. Patients who have been exposed to Fampyra in the past Patients with an MS attack within last 3 months